Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (201-210 of 324) with videos related to

Pageof 33
Sort By:
Plos One|February 22, 2018
The clinical characteristics of adults with rheumatic heart disease in Yangon, Myanmar: An observational studyNan Phyu Sin Toe Myint, Ne Myo Aung, Myint Soe Win, et al.
BMC Public Health|March 2, 2018
Correction: expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in new South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trialIryna B Zablotska, Christine Selvey, Rebecca Guy, et al.
Antiviral Therapy|April 28, 2017
Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trialAmanda H Yao, Cecilia L Moore, Poh Lian Lim, et al.
BMC Public Health|February 4, 2018
Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trialIryna B Zablotska, Christine Selvey, Rebecca Guy, et al.
AIDS (London, England)|April 15, 2015
The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levelsElizabeth Hamlyn, Wolfgang Stöhr, David A Cooper, et al.
The Journal of Antimicrobial Chemotherapy|August 13, 2016
Improved adipose tissue function with initiation of protease inhibitor-only ARTRobert T Maughan, Eoin R Feeney, Emilie Capel, et al.
AIDS (London, England)|March 14, 2012
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwardsJohn M Murray, Kristin McBride, Christoph Boesecke, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 14, 2025
Optimized chemical structure extends silencing duration of therapeutic siRNAs in dividing cancer and immune cellsAnastasia Kremer, Tatyana Ryaykenen, Xavier Segarra-Visent, et al.
AIDS (London, England)|August 30, 2008
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switchingJulian H Elliott, Lut Lynen, Alexandra Calmy, et al.
Frontiers in Immunology|November 9, 2016
CD4<sup>+</sup> T Follicular Helper and IgA<sup>+</sup> B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected IndividualsJohn Zaunders, Mark Danta, Michelle Bailey, et al.
Pageof 33

Showing results (201-210 of 324) with videos related to

Sort By:
Pageof 33
Plos One|February 22, 2018
The clinical characteristics of adults with rheumatic heart disease in Yangon, Myanmar: An observational studyNan Phyu Sin Toe Myint, Ne Myo Aung, Myint Soe Win, et al.
BMC Public Health|March 2, 2018
Correction: expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in new South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trialIryna B Zablotska, Christine Selvey, Rebecca Guy, et al.
Antiviral Therapy|April 28, 2017
Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trialAmanda H Yao, Cecilia L Moore, Poh Lian Lim, et al.
BMC Public Health|February 4, 2018
Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trialIryna B Zablotska, Christine Selvey, Rebecca Guy, et al.
AIDS (London, England)|April 15, 2015
The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levelsElizabeth Hamlyn, Wolfgang Stöhr, David A Cooper, et al.
The Journal of Antimicrobial Chemotherapy|August 13, 2016
Improved adipose tissue function with initiation of protease inhibitor-only ARTRobert T Maughan, Eoin R Feeney, Emilie Capel, et al.
AIDS (London, England)|March 14, 2012
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwardsJohn M Murray, Kristin McBride, Christoph Boesecke, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 14, 2025
Optimized chemical structure extends silencing duration of therapeutic siRNAs in dividing cancer and immune cellsAnastasia Kremer, Tatyana Ryaykenen, Xavier Segarra-Visent, et al.
AIDS (London, England)|August 30, 2008
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switchingJulian H Elliott, Lut Lynen, Alexandra Calmy, et al.
Frontiers in Immunology|November 9, 2016
CD4<sup>+</sup> T Follicular Helper and IgA<sup>+</sup> B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected IndividualsJohn Zaunders, Mark Danta, Michelle Bailey, et al.
Pageof 33